Doctors Warn of 'Two-Tier' Weight Loss Jab System in Scotland

Doctors are raising concerns about a potential 'two-tier system' for accessing weight loss medications in Scotland, as new figures reveal that only 705 patients have received these injectable drugs through the National Health Service (NHS) over the past three years. These medications, considered a significant advancement in managing obesity and type II diabetes, are largely unavailable to the majority of those who could benefit.

Professor Mark Strachan, President of the Royal College of Physicians of Edinburgh, highlighted the transformative impact of these drugs, noting that they can reduce the risk of major cardiovascular events by approximately 20% or more in eligible patients. He also observed significant weight loss, sometimes exceeding three stones, and positive impacts on both physical and mental health among his patients. However, he pointed out that many individuals in Scotland who would benefit from these medicines cannot access them through the NHS for weight management.

This situation, Strachan warned, may create a disparity where financially well-off individuals can afford weight loss medicines through private prescriptions, while those in more deprived communities, who may disproportionately bear the burden of obesity and type II diabetes, face greater barriers to access. The Simple Online Pharmacy estimates that around 300,000 Scots are paying for these drugs privately, with annual costs potentially exceeding £4,000.

Mounjaro was approved for NHS weight-management use in Scotland in 2024, and Wegovy followed in 2023. Despite these approvals, only five of Scotland's 14 regional health boards are utilizing these diet-suppressant drugs. Their use is confined to small pilot programs, a stark contrast to the more widespread GP prescription seen in England and Wales. Across the UK, an estimated two million individuals use weight loss jabs, primarily through private prescriptions. Data from Private GP Clinic suggests that 280,000 people in the UK have accessed weight loss injections via the NHS, meaning Scottish patients account for a mere 0.25% of this total.

Public Health Minister Maree Todd stated that decisions regarding the implementation and availability of medicines, including those for obesity, rest with individual health boards. She explained that each NHS area makes these decisions based on national consensus statements that recommend a phased introduction of obesity medicines, contingent on a patient's body mass index and the presence of obesity-related conditions.

Obesity affects a third of Scotland's population and is linked to serious health issues such as cardiovascular disease, cancer, and diabetes. The economic impact of excess weight on the taxpayer is estimated at £5.3 billion annually, covering costs for the NHS, social work, and unemployment benefits. Data consistently shows that individuals with lower incomes are more likely to struggle with excess weight.

Weight loss drugs, known as GLP-1 agonists, function by mimicking a natural hormone that helps regulate appetite, leading to reduced food intake and significant weight loss. Despite their proven efficacy and potential to alleviate the health and economic burdens of obesity, their limited availability through the NHS in Scotland is a growing concern among medical professionals.